Sarcopenia is defined as a loss of skeletal muscle mass and strength, and is believed to mostly affect older individuals. Muscle mass decreases with age, with a 0.5% to 1.0% reduction in muscle mass per year after 70 years of age. Sarcopenia is present in about one quarter to one half of men and women older than 65 years, but may occur earlier causing adverse health outcomes due to low muscle mass and strength. Sarcopenia increases the risks of falls, fractures, disability, and functional impairments, as well as mortality. In addition, individuals with sarcopenia have higher insulin resistance and are at increased risk of diabetes and cardiovascular disease than non-sarcopenic individuals. Because women have a longer lifespan than men, women are more likely to experience the negative muscular changes associated with aging.

The aging process is often accompanied by comorbid conditions that contribute to the development of sarcopenia. Age-related reductions in anabolic hormones such as testosterone, growth hormone, and insulin-like growth factor-1 have been shown to be associated with muscle loss. Although sarcopenia is highly prevalent in postmenopausal women, whether decline of estrogen contributes to development of sarcopenia in postmenopausal women is not determined. Accelerated muscle loss is associated with the menopausal transition, suggesting that hormone supplementation may prevent or reduce loss in muscle mass. To our knowledge, few large-scale studies have assessed the ability of HT use to attenuate muscle loss in postmenopausal women.

ORIGINAL STUDY

The association between hormone therapy and sarcopenia in postmenopausal women: the Korea National Health and Nutrition Examination Survey, 2008-2011

Sung-Woo Kim, MD,1 and Rebecca Kim, MD2

Abstract

Objective: Menopausal transition contributes to sarcopenia, but the effects of hormone therapy (HT) on sarcopenia in postmenopausal women have not been determined. This study assessed the effect of HT on sarcopenia in postmenopausal women.

Methods: The present study included 4,254 postmenopausal women who participated in the Korea National Health and Nutrition Examination Surveys from 2008 to 2011. Appendicular skeletal muscle mass divided by weight (ASM/Wt) and the prevalence of sarcopenia were analyzed in groups of women stratified by duration of HT use.

Results: ASM/Wt was higher and the prevalence of sarcopenia was lower in participants with a history of prolonged (≥ 13 mo) HT use than in participants with a shorter duration of HT use or no HT use. After adjusting for multiple confounding factors, prolonged use of HT remained significantly associated with estimated mean ASM/Wt and the prevalence of sarcopenia (odds ratio: 0.60; 95% confidence interval: 0.41-0.88; P = 0.01). In addition, the prevalence of sarcopenia was linearly associated with history of hypertension, duration of hypertension, physical activity, and duration of HT use. Subgroup analysis showed that the association between duration of HT use and the prevalence of sarcopenia was maintained in younger (<65 y old) and leaner (body mass index <25 kg/m2) postmenopausal women.

Conclusions: The present study showed that the prolonged use of HT was associated with high muscle mass and a low prevalence of sarcopenia in postmenopausal women.

Key Words: Appendicular skeletal muscle mass – Hormone therapy – Sarcopenia.
postmenopausal women. The present study therefore evaluated whether the duration of HT use was associated with muscle mass and the prevalence of sarcopenia in postmenopausal women.

**MATERIALS AND METHODS**

**Participants**
This study was based on data from the Korea National Health and Nutrition Examination Survey (KNHANES) collected from 2008 to 2011. KNHANES is a cross-sectional, population-based, nationwide survey conducted by the Division of Chronic Disease Surveillance of the Korea Centers for Disease Control and Prevention. Of the 20,698 participants who underwent dual-energy x-ray absorptiometry (DXA; QDR 4500A; Hologic Inc., Waltham, MA), 4,254 postmenopausal women were initially selected. After excluding participants with incomplete information on HT use, 4,233 postmenopausal women were enrolled, and the association between HT use and sarcopenia was assessed in this population. The KNHANES was approved by the Institutional Review Board of the KCDC (IRB No: 2008-04EXP-01-C, 2009-01CON-03-2C, 2010-02CON-21-C, and 2011-02CON-06C), and all participants provided written informed consent before participation.

**Measurements of biochemical and clinical parameters**
Appendicular skeletal muscle mass (ASM), defined as the sum of lean soft tissue mass (nonfat and nonbone mass) of the arms and legs, was measured using DXA.\(^2^4\) DXA calibrations were maintained through an internal referencing system, which periodically measures bone and soft tissue equivalent reference standards during the examination of the participants. ASM/Wt was calculated as ASM divided by weight. Sarcopenia was defined as an ASM/Wt less than one standard deviation below the mean for healthy adults aged 20 to 39 years. The cut off value for sarcopenia in women was 25.6%\(^1^1,2^5\). Body mass and height were measured by trained staff, and body mass index (BMI) was calculated as body mass (kg) divided by height squared (m\(^2\)). Demographic and personal medical data were collected using standardized health questionnaires. The health interview was conducted by trained staff members, including physicians, medical technicians, and health interviewers. These data included reproductive factors (age at menarche, age at menopause, number of pregnancies, history of oral contraceptive [OC] use, and history of HT use), history of hypertension (HTN) and diabetes mellitus (DM), smoking history (current or ex-), and physical activity (walk/moderate/high). Nutrient status (total energy intake, protein intake, carbohydrate intake, and fat intake) was determined using a 24-hour dietary recall questionnaire.

**Statistical analysis**
All analyses were performed using the Complex Samples Plan in SPSS version 18.0 software (IBM, Armonk, NY) according to the KNHANES data analysis guidelines. The data were weighted, stratified, and clustered. The sample represents the total noninstitutionalized civilian population of Korea. Participants were stratified according to the duration of HT use (none, 1-12 mo, and $\geq$13 mo). The groups were compared in terms of demographic and clinical variables by using analysis of variance and Chi-square test. Complex Samples General Linear Model was used to evaluate the estimated mean of ASM and ASM/Wt among HT use groups. The association between HT use and the prevalence of sarcopenia was estimated using Complex Samples Logistic Regression. To assess which factors are independently associated with ASM/Wt and the prevalence of sarcopenia, Complex Samples General Linear Model, and Complex Samples Logistic Regression were used for analysis. All continuous data are presented as mean ± standard error, and all categorical data as unweighted numbers and weighted prevalence. \(P < 0.05\) was regarded as statistically significant.

**RESULTS**

**General characteristics of postmenopausal women stratified by duration of hormone therapy use**
The general characteristics of participants are presented in Table 1. Of the 4,233 participants, 3,656 (86.4%) received no HT, 302 (7.1%) were treated with HT for 1 to 12 months (mean, 5.2 ± 0.28 mo), and 275 (6.5%) received HT for more than 13 months (mean, 52.8 ± 2.90 mo). Participants with a history of HT use were significantly younger than participants without a history of HT use. Mean BMI did not differ significantly among the three groups. Participants with a history of prolonged HT use were younger at menarche and older at menopause than participants in the other groups. Thus, duration of menstruation was significantly longer and duration of menopause was shorter in the prolonged HT use group. The number of pregnancies was lower in participants who received HT for 1 to 12 months than in participants who received no HT. History of OC use was significantly more frequent in participants with than without a history of HT use. Intake of nutrients, including intake of total energy, protein, carbohydrate, and fat, was significantly greater in participants with a prolonged history of HT use. Previous histories of DM and HTN were less frequent in participants who received HT for 1 to 12 months than in the other groups. The age of diagnosis of DM and HTN was older in non-HT users, but duration of DM and HTN was longer in non-HT users than in HT users. History of smoking and physical activity did not differ in the three groups. ASM and ASM/Wt were significantly higher, and the prevalence of sarcopenia was significantly lower, in participants with a prolonged history of HT use than in the other two groups.

**Association between hormone therapy and appendicular skeletal muscle mass**
After adjusting for multiple confounding factors, the estimated means of ASM and ASM/Wt were compared in the three groups of participants (Fig. 1). The model was adjusted for age, age at menarche, age at menopause, duration of
HORMONE THERAPY AND SARCOPENIA

TABLE 1. Demographic and characteristics of postmenopausal women stratified by duration of hormone therapy

|                                      | No HT use (n = 3,656) | HT use for 1-12 mo (n = 302) | HT use for ≥13 mo (n = 275) | P     |
|--------------------------------------|-----------------------|------------------------------|----------------------------|-------|
| Age, y                               | 64.5 ± 0.25           | 57.2 ± 0.69b                 | 59.8 ± 0.48b                | <0.01 |
| BMI, kg/m²                           | 24.1 ± 0.07           | 23.7 ± 0.23                  | 23.8 ± 0.18                 | 0.07  |
| Reproductive factors                 |                       |                              |                            |       |
| Age at menarche, y                   | 16.0 ± 0.05           | 15.5 ± 0.14b                 | 15.5 ± 0.13b                | <0.01 |
| Age at menopause, y                  | 49.1 ± 0.10           | 48.7 ± 0.37                  | 50.0 ± 0.42b                | 0.08  |
| Duration of menstruation, y          | 33.1 ± 0.11           | 33.2 ± 0.39                  | 34.4 ± 0.44b                | 0.02  |
| Duration of menopause, y             | 15.0 ± 0.30           | 8.2 ± 0.56e                  | 9.8 ± 0.48b                 | <0.01 |
| Number of pregnancies, n             | 5.0 ± 0.05            | 4.5 ± 0.18b                  | 5.0 ± 0.19                  | 0.01  |
| Past history of OC use, n            | 729 (20.0%)           | 95 (33.4%)b                  | 88 (33.8%)b                 | <0.01 |
| Duration of OC use, mo               | 20.7 ± 1.54           | 12.4 ± 1.52                  | 13.4 ± 2.52                 | 0.01  |
| Duration of HT use, mo               | 0                     | 5.2 ± 0.28b                  | 52.8 ± 2.90b                | <0.01 |
| Nutrient status                      |                       |                              |                            |       |
| Energy intake, kcal                  | 1513.3 ± 15.51        | 1530.0 ± 46.33               | 1670.2 ± 46.63              | <0.01 |
| Protein, g                           | 50.3 ± 0.63           | 54.5 ± 2.23                  | 59.7 ± 1.99b                | <0.01 |
| Carbohydrate, g                      | 282.3 ± 3.00          | 276.8 ± 7.42                 | 303.0 ± 8.83b               | 0.07  |
| Fat, g                               | 21.6 ± 0.49           | 24.6 ± 1.51                  | 271.1 ± 1.22b               | <0.01 |
| Medical history                      |                       |                              |                            |       |
| DM, n                                | 488 (13.5%)           | 26 (7.3%)b                   | 27 (10.1%)                  | <0.01 |
| Age at diagnosis with DM, y          | 58.6 ± 0.67           | 54.8 ± 1.46b                 | 56.5 ± 1.87                 | 0.05  |
| Duration of DM, y                    | 8.4 ± 0.40            | 6.7 ± 1.07                   | 6.2 ± 1.10                  | 0.07  |
| HTN, n                               | 1501 (40.4%)          | 107 (30.9%)a                 | 93 (37.5%)                  | 0.03  |
| Age at diagnosis with HTN, y         | 60.2 ± 0.37           | 54.2 ± 0.91a                 | 56.5 ± 0.94                 | <0.01 |
| Duration of HTN, y                   | 7.9 ± 0.23            | 7.4 ± 0.73                   | 6.2 ± 0.61b                 | 0.03  |
| Social history                       |                       |                              |                            |       |
| Smoking, n (current/ex-)             | 171/145 (5.5%/4.6%)   | 8/14 (2.9%/5.2%)             | 7/10 (3.9%/2.3%)            | 0.16  |
| Physical activity, n (walk/moderate/high) | 1444/483/387 (40%/12.7%/11.5%) | 116/44/40 (37.7%/16.5%/14.3%) | 112/32/33 (43.4%/12.4%/10.8%) | 0.77  |
| Sarcopenia                           |                        |                              |                            |       |
| ASM, kg                              | 13.9 ± 0.05           | 14.2 ± 0.13b                 | 14.6 ± 0.14b                | <0.01 |
| ASM/Wt, %                            | 24.8 ± 0.08           | 24.8 ± 0.19                  | 25.1 ± 0.17b                | 0.13  |
| Sarcopenia, n                        | 2303 (66.1%)          | 201 (64.4%)                  | 165 (56.7%)                 | 0.09  |

Continuous variables are presented as mean ± standard error, and categorical variables as unweighted number (weighted prevalence). ASM, appendicular skeletal muscle mass; ASM/Wt, appendicular skeletal muscle mass divided by weight; BMI, body mass index; DM, diabetes mellitus; HT, hormone therapy; HTN, hypertension; OC, oral contraceptive.

*P < 0.01.

**P < 0.05.

menstruation and menopause, number of pregnancies, history of OC use, duration of OC use, past history of DM and HTN, duration of HTN and DM, smoking history, physical activity, and nutrient intake (total, proteins, carbohydrates, and fats). The model showed lower ASM by category of self-reported HT use for 13 months or more (Fig. 1A). The estimated mean ASM/Wt was also significantly higher in participants who received HT for 13 months or more than in the other groups (Fig. 1B).

Association between hormone therapy and sarcopenia

Table 2 shows the odds ratios (ORs) and 95% confidence intervals (CIs) for sarcopenia. In an unadjusted model, the OR for sarcopenia was significantly lower in the group that received HT for 13 months or more than in the other groups (OR = 0.67; 95% CI, 0.47-0.95; P < 0.05). After adjustment for reproductive factors, medical history, social history, and nutrient factors, the association of HT use with the prevalence of sarcopenia was still significant (OR = 0.60; 95% CI, 0.41-0.88; P = 0.01).

Association of appendicular skeletal muscle mass and sarcopenia with variable factors

Table 3 presents multivariate analysis estimates, the association of multiple variables with ASM/Wt, and the prevalence of sarcopenia. History of DM, duration of DM, history of HTN, duration of HTN, smoking history, and physical activity were associated with ASM/Wt. In reproductive factors, history of HT use was associated with ASM/Wt, but duration of HT use was not associated with ASM/Wt. History of HTN, duration of HTN, and physical activity were independently associated with the prevalence of sarcopenia. In addition, duration of HT use was linearly associated with the prevalence of sarcopenia (OR = 0.994 per 1 mo; 95% CI, 0.989-0.999; P = 0.02).

Association between hormone therapy and sarcopenia in different subgroups

Evaluation of the association between the duration of HT use and the prevalence of sarcopenia in groups of participants differing by age and BMI (Table 4) showed that the ORs for sarcopenia in older participants (≥65 y) did not differ among the three HT use groups. In younger participants (<65 y), however, the OR for sarcopenia was significantly lower in the group that received HT for 13 months or more than in the group that did not receive HT. Regardless of BMI subgroup, the OR for sarcopenia was lower in participants who received prolonged treatment with HT than in participants who did not receive HT, but statistical significance was only observed in participants with BMI <25 kg/m².
FIG. 1. Estimated means of (A) appendicular skeletal muscle mass and (B) appendicular skeletal muscle mass divided by weight in each hormone therapy group after adjusting for multiple confounding factors. Data were analyzed using Complex Samples General Linear Models and are expressed as mean ± standard error. Adjusted model: age, age at menarche, age at menopause, duration of menstruation and menopause, number of pregnancies, past history of OC use, duration of OC use, past histories of DM and HTN, smoking history, physical activity, and energy intake (total, proteins, carbohydrates, and fats). ASM/Wt, appendicular skeletal muscle mass divided by weight; DM, diabetes mellitus; HT, hormone therapy; HTN, hypertension; OC, oral contraceptive.

TABLE 2. Odds ratios for the prevalence of sarcopenia in postmenopausal women stratified by duration of hormone therapy

|                        | No HT use (n = 3,656) | HT use for 1-12 mo (n = 302) | HT use for ≥ 13 mo (n = 275) | P for trend |
|------------------------|-----------------------|-------------------------------|-------------------------------|------------|
| Unadjusted             | 1 (ref)               | 0.93 (0.68-1.27)              | 0.67 (0.47-0.95)*             | 0.03       |
| Model 1                | 1 (ref)               | 0.95 (0.69-1.31)              | 0.64 (0.45-0.92)*             | 0.03       |
| Model 2                | 1 (ref)               | 0.93 (0.68-1.28)              | 0.60 (0.41-0.88)*             | 0.02       |
| Model 3                | 1 (ref)               | 0.90 (0.66-1.24)              | 0.59 (0.40-0.87)*             | 0.01       |
| Model 4                | 1 (ref)               | 0.89 (0.65-1.23)              | 0.60 (0.41-0.88)*             | 0.01       |

Data were analyzed using Complex Samples Logistic Regression and are expressed as odds ratio (95% confidence interval).

Model 1: adjusted for age, age at menarche, age at menopause, and number of pregnancies.
Model 2: adjusted for age, age at menarche, age at menopause, number of pregnancies, past history of OC use, past histories of DM and HTN, smoking history, and physical activity.
Model 3: adjusted for age, age at menarche, age at menopause, number of pregnancies, past history of OC use, past histories of DM and HTN, smoking history, physical activity, and energy intake (total, proteins, carbohydrates, and fats).
Model 4: adjusted for age, age at menarche, age at menopause, duration of menstruation and menopause, number of pregnancies, past history of OC use, past histories of DM and HTN, duration of HTN and DM, smoking history, physical activity, and energy intake (total, proteins, carbohydrates, and fats).

DM, diabetes mellitus; HT, hormone therapy; HTN, hypertension; OC, oral contraceptive.

*P < 0.01.

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc., on behalf of The North American Menopause Society.
HORMONE THERAPY AND SARCOPENIA

TABLE 3. The association of appendicular skeletal muscle divided by weight and prevalence of sarcopenia with multiple variables

|                        | ASM/Wt |          | Sarcopenia |          |
|------------------------|--------|----------|------------|----------|
|                        | B (t value) | P     | ORs         | P       |
| Age, y                 | 0.014 (0.486) | 0.63 | 1.001 (0.957-1.048) | 0.96   |
| Nutrient status        |         |         |            |         |
| Energy intake, kcal    | 0.001 (1.721) | 0.09 | 0.999 (0.997-1.000) | 0.06   |
| Protein intake, g      | 0.007 (1.508) | 0.13 | 1.004 (1.000-1.015) | 0.06   |
| Carbohydrate intake, g | 0.002 (0.846) | 0.40 | 1.004 (0.998-1.009) | 0.18   |
| Fat intake, g          | 0.015 (2.152) | 0.03 | 1.012 (0.997-1.027) | 0.11   |
| Medical history        |         |         |            |         |
| History of DM          | 0.601 (2.691) | <0.01 | 1.280 (0.844-1.942) | 0.24   |
| Duration of DM, y      | 0.039 (2.121) | 0.03 | 0.984 (0.950-1.019) | 0.38   |
| History of HTN         | 0.857 (6.285) | <0.01 | 1.892 (1.448-2.473) | <0.01  |
| Duration of HTN, y     | 0.038 (-0.382) | <0.01 | 1.034 (1.009-1.060) | <0.01  |
| Social history         |         |         |            |         |
| Smoking history        | 0.374 (3.336) | <0.01 | 0.879 (0.725-1.067) | 0.19   |
| Physical activity      | 0.186 (3.637) | <0.01 | 0.883 (0.808-0.964) | <0.01  |
| Reproductive factors   |         |         |            |         |
| Duration of menstruation, y | 0.026 (-0.856) | 0.39 | 1.009 (0.968-1.051) | 0.68   |
| Duration of menopause, y | 0.005 (0.186) | 0.85 | 0.984 (0.940-1.030) | 0.49   |
| Past history of pregnancy | -0.546 (-1.451) | 0.15 | 1.314 (0.582-2.963) | 0.51   |
| Duration of OC use, mo | 0.001 (0.290) | 0.77 | 0.998 (0.990-1.006) | 0.61   |
| History of HT use      | 0.222 (2.440) | 0.02 | 0.803 (0.676-0.954) | 0.01   |
| Duration of HT use, mo | 0.004 (1.628) | 0.10 | 0.994 (0.989-0.999) | 0.02   |

Data were analyzed using Complex Samples General Linear Models and Complex Samples Logistic Regression. ASM/Wt, appendicular skeletal muscle divided by weight; DM, diabetes mellitus; HT, hormone therapy; HTN, hypertension; OC, oral contraceptive; OR, odds ratio.

*P < 0.01.

Table 4: Odds ratios of the prevalence of sarcopenia in postmenopausal women stratified by duration of hormone therapy in age and body mass index subgroups

| Age ≥65 y | No HT use | 1,222 (65.1%) | 1 (Reference) | 1 (Reference) |
|-----------|-----------|---------------|---------------|---------------|
| HT use 1-12 mo | 58 (76.2%) | 1.72 (0.86-3.43) | 1.25 (0.60-2.63) |
| HT use ≥13 mo | 55 (69.2%) | 1.20 (0.53-2.71) | 0.84 (0.39-1.81) |
| Age <65 y  | No HT use | 1,081 (66.9%) | 1 (Reference) | 1 (Reference) |
| HT use 1-12 mo | 143 (61.9%) | 0.80 (0.56-1.15) | 0.86 (0.60-1.23) |
| HT use ≥13 mo | 110 (52.8%) | 0.55 (0.37-0.83) | 0.56 (0.36-0.86) |
| BMI ≥25 kg/m² | No HT use | 1,151 (87.8%) | 1 (Reference) | 1 (Reference) |
| HT use 1-12 mo | 86 (83.6%) | 0.71 (0.35-1.43) | 0.87 (0.40-1.87) |
| HT use ≥13 mo | 70 (82.0%) | 0.64 (0.31-1.32) | 0.61 (0.28-1.31) |
| BMI <25 kg/m²  | No HT use | 1,152 (53.3%) | 1 (Reference) | 1 (Reference) |
| HT use 1-12 mo | 115 (56.5%) | 1.14 (0.76-1.70) | 1.05 (0.71-1.55) |
| HT use ≥13 mo | 95 (45.4%) | 0.73 (0.48-1.11) | 0.65 (0.42-1.00) |

Data were analyzed using Complex Samples Logistic Regression and are expressed as unweighted number (weighted prevalence) and odds ratio (95% confidence interval).

Model adjusted for age, at menarche, age at menopause, duration of menstruation and menopause, number of pregnancies, past history of OC use, duration of OC use, past histories of DM and HTN, duration of HTN and DM, smoking history, physical activity, and energy intake (total, proteins, carbohydrates, and fats).

BMI, body mass index; HT, hormone therapy; DM, diabetes mellitus; HT, hormone therapy; HTN, hypertension; OC, oral contraceptive.

*P < 0.01.

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc., on behalf of The North American Menopause Society.
CONCLUSION

The present study showed that prolonged use of HT was associated with higher muscle mass and lower prevalence of sarcopenia in postmenopausal women.

Acknowledgments: The authors thank all the women who participated in this study.

REFERENCES

1. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med 2001;137:231-243.
2. Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength: a quantitative review. Front Physiol 2012;3:260.
3. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. J Am Geriatr Soc 2004;52:139-413-421.
4. Sayer AA, Syddall H, Martin H, Patel H, Baylis D, Cooper C. The developmental origins of sarcopenia. J Nutr Health Aging 2008;12:427-432.
5. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31.
6. Scott D, Hayes A, Sanders KM, Aitken D, Ebeling PR, Jones G. Operational definitions of sarcopenia and their associations with 5-year changes in falls risk in community-dwelling middle-aged and older adults. Osteoporos Int 2014;25:187-193.
7. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002;50:889-896.
8. Garbilda S, Alessa A. Sarcopenia: prevalence and prognostic significance in hospitalized patients. Clin Nutr 2013;32:772-776.
9. Landi F, Cruz-Jentoft AJ, Liperoti R, et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from IS-SIRENE study. Age Ageing 2013;42:203-209.
10. Park SW, Goodpaster BH, Lee JS, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 2009;32:1993-1997.
11. Chin SO, Rhee SY, Chon S, et al. Sarcopenia is independently associated with cardiovascular disease in older Korean adults: the Korea National Health and Nutrition Examination Survey (KNHANES) from 2009. PLoS One 2013;8:e6019.
12. Han F, Yu H, Ma Y, et al. The increased risk of sarcopenia in patients with cardiovascular risk factors in Suburb-Dwelling older Chinese using the AWGS definition. Sci Rep 2017;7:9592.
13. Ngefeu A, Allafi F, Medrare L, Madhi A, Rkain H, Hajaj-Hassouni N. Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors. Rheumatol Int 2017;37:1015-1020.
14. He WA, Berardi E, Cardillo VM, et al. NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest 2013;123:4821-4835.
15. Sattler FR, Castaneda-Sceppa C, Binder EF, et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab 2009;94:1991-2001.
16. Brioche T, Kireev RA, Cuesta S, et al. Growth hormone replacement therapy prevents sarcopenia by a dual mechanism: improvement of protein balance and of antioxidant defenses. J Gerontol A Biol Sci Med Sci 2014;69:1186-1198.
17. Messier V, Rahasia-Lhoret R, Barbat-Artigas S, Elisha B, Karelis AD, Aubertin-Leheudre M. Menopause and sarcopenia: a potential role for sex hormones. Maturitas 2011;68:331-336.
18. Carson JA, Manolagas SC. Effects of sex steroids on bones and muscles: similarities, parallels, and putative interactions in health and disease. Bone 2015;80:67-78.
19. Tanko LB, Movsesyan L, Svendsen OL, Christiansen C. The effect of hormone replacement therapy on appendicular lean tissue mass in early postmenopausal women. Menopause 2002;9:117-121.
20. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002;87:1509-1516.
21. Grees JP, Cable NT, Reilly T, Kingsland C. Changes in muscle strength in women following the menopause: a longitudinal assessment of the efficacy of hormone replacement therapy. Clin Sci (Lond) 1999;97:79-84.
22. Bemben DA, Langdon DB. Relationship between estrogen use and musculeskeletal function in postmenopausal women. Maturitas 2002;42:119-127.
23. Javed AA, Mayhew AJ, Shea AK, Raina P. Association between hormone therapy and muscle mass in postmenopausal women: a systematic review and meta-analysis. JAMA Netw Open 2019;2:e1910154.
24. Heymsfield SB, Smith R, Aulet M, et al. Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr 1990;52:214-218.
25. Lim S, Kim JH, Yoon JY, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care 2010;33:1652-1654.
26. Taaffe DR, Newman AB, Haggerty CL, et al. Estrogen replacement, muscle composition, and physical function: The Health ABC Study. Med Sci Sports Exerc. 2005;37:1741-1747.
27. Lemoine S, Granier P, Toufoche C, Rannou-Bekono F, Thieltz ML, Delannarache P. Estrogen receptor alpha mRNA in human skeletal muscles. Med Sci Sports Exerc 2003;35:439-443.
28. Friend KE, Hartman ML, Pezzoli SS, Caseley J, Thormer MO. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women – a clinical research center study. J Clin Endocrinol Metab 1996;81:2250-2256.
29. D’Eon T, Braun B. The roles of estrogen and progesterone in regulating body composition in early postmenopausal women. Menopause 2002;9:117-121.
30. Greising SM, Baltgalvis KA, Lowe DA, Warren GL. Hormone therapy prevents sarcopenia by a dual mechanism: improvement of protein balance and of antioxidant defenses. J Gerontol A Biol Sci Med Sci 2014;69:1186-1198.
31. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Menopause 2001;8:125-132.
32. Mautner WJ, Watts DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Aging Dev 1999;107:123-136.

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc., on behalf of The North American Menopause Society.